Document is current

Article History

Received: 23 December 2024

Accepted: 24 November 2025

First Online: 5 January 2026

Competing interests

: P.Strati reports consultancy for Kite, Roche-Genentech, Hutchison MediPharma, ADC Therapeutics, Incyte Morphosis and TG Therapeutics and research funding from Sobi Pharmaceuticals, AstraZeneca-Acerta, ALX Oncology and ADC Therapeutics. L.L. reports consultancy for and travel support from AbbVie, AstraZeneca, Merck, TG Therapeutics, Janssen, Epizyme, Kite, Celgene, Pharmacyclics, Bristol Myers Squibb, ADC Therapeutics, BeiGene and Seattle Genetics, speakers’ bureau participation for and travel support from Kite, BeiGene, Pharmacyclics, Janssen, AstraZeneca, Seattle Genetics, TG Therapeutics, Epizyme, Karyopharm, Celgene and Bristol Myers Squibb and participation on the data safety advisory board for TG Therapeutics, AbbVie, Pharmacyclics, Janssen, AstraZeneca, Seattle Genetics and ADC Therapeutics. P.Shiraz reports research funding from Kite and Orca Bio. L.E.B. reports honoraria from Kite, a consultancy or advisory role for Kite, Gilead and Roche, speakers’ bureau participation for Kite and AstraZeneca and research funding from MustangBio, Merck, Amgen and AstraZeneca. O.O.O. reports a consultancy or advisory role for Kite, Janssen, Pfizer, Novartis and Curio Science and honoraria and research funding from Kite. M.U. reports advisory board participation for Gilead and Stemline. A.R. reports honoraria from Cigna, Amgen and Takeda, a consultancy or advisory role for Amgen, AstraZeneca, GenMab, Novartis and Takeda and speakers’ bureau participation for Takeda. T.Z. and J.S. report employment with Kite. F.M. reports employment with and research funding from Kite and Gilead and stock or other ownership in Gilead. J.K. and H.X. report employment with Kite and stock or other ownership in Gilead. R.S. reports employment and leadership role with Kite and Atara, stock or other ownership in Gilead and Atara and patents, royalties and other intellectual property from Kite. F.N. reports prior employment with Kite and stock or other ownership in Gilead. K.P. reports consultancy for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Fate Therapeutics, Genentech/Roche, Janssen/Pharmacyclics, Kite, Lilly/Loxo Oncology, Merck, MorphoSys, Sana Pharma and Xencor, research funding (to institution) from AbbVie, Adaptive Biotechnologies, Adicet Bio, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Cargo Therapeutics, Fate Therapeutics, Genentech/Roche, Janssen/Pharmacyclics, Kite, Lilly/Loxo Oncology, Merck, Nurix, Sana Pharma and Xencor and speakers’ bureau participation for AstraZeneca, Bristol Myers Squibb and Kite.